Merck & Co. agreed to acquire cancer developer Imago BioSciences Inc. in a deal valued at $1.35 billion. The deal will add new revenue streams as Merck’s patent deal for cancer treatment Keytruda is set to expire early next year and grow its presence in the hematology field. (Articles here and here)